CRISPR Therapeutics AG

Key Statistics

Recent News

• CRISPR Therapeutics Expands Funding Capacity As Gene Editing Pipeline Advances Simply Wall St.

  CRISPR Therapeutics (NasdaqGM:CRSP) filed a large shelf registration, creating capacity to issue new securities over time. Shareholders approved amendments to the articles of association, allowing for

• CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts Zacks

  In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.

• CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks

  CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.

• CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? Motley Fool

  The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

• CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline Insider Monkey

  CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 27, research firm Citizens reiterated a Market Perform rating and a $60 price target on

• Eli Lilly Pressure And RNA Expansion Reframe CRISPR Therapeutics Outlook Simply Wall St.

  Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive pressure on CRISPR Therapeutics' CTX310 program. CRISPR Therapeutics (NasdaqGM

• CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential Motley Fool

  Its revolutionary CASGEVY treatment could be a sign of what's to come.

• Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report? Zacks

  CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.